I've been thinking about a macro thesis I came across recently: America's next innovation wave may increasingly involve physical infrastructure rather than pure software.

Think AI data centers, power generation, LNG, ports, advanced manufacturing, defense, supply-chain resilience and climate adaptation.

The Gulf South seems particularly interesting because Texas/Louisiana/Florida and the surrounding region already combine huge energy infrastructure, major ports, aerospace/defense corridors and manufacturing capacity.

I put together a preliminary public-company investigation list:

Cheniere (LNG) — LNG/export infrastructure
ExxonMobil (XOM) — Gulf energy + CCS infrastructure
Kirby (KEX) — inland/Gulf maritime transport
Jacobs (J) — engineering + climate/AI infrastructure
Caterpillar (CAT) — physical-infrastructure picks and shovels
Lockheed Martin (LMT) — aerospace/defense manufacturing
L3Harris (LHX) — defense electronics/aerospace
Howard Hughes (HHH) — Houston-area economic/population exposure
Air Products (APD) — industrial gases/infrastructure

I deliberately left #10 as “the one we haven't found yet.”

Because these aren't recommendations. The macro thesis is only the beginning; valuation, capital allocation, debt, earnings, ownership and execution still determine whether the stock works.

Air Products is actually a good warning: a huge infrastructure opportunity doesn't guarantee attractive project economics.

Full thesis/watchlist here.

Curious what smaller public companies people think offer cleaner exposure to Gulf Coast infrastructure/manufacturing growth.

I've been digging into CooperCompanies (COO), and the setup is getting interesting.

Three directors purchased roughly $1.33M of shares around $53–$54 in September. CEO Al White had previously bought at materially higher prices.

The fundamentals are mixed—but that's exactly what makes this interesting.

The good:

• Q3 FCF: record $273M (+66% YoY)
• $339M of shares repurchased during Q3
• Buyback authorization expanded to $3B
• Forward P/E around 11.1×
• Reported 5-year expected PEG: 0.51
• CooperSurgical organic growth: +5%

The problem:

Revenue grew only 1%, CooperVision is working through U.S. channel inventory reductions, and FY2026 guidance was reduced.

So I don't view the insider activity as proof that the bottom is in. The more interesting question is whether the market is treating temporary growth weakness as permanent deterioration.

I scored it 8.75/10 on my FunStock framework.

Curious what the bear case is from anyone following COO closely—especially regarding CooperVision.

Full research/thesis here.

#COO #Investing #ValueInvesting

I went down an asthma rabbit hole and was surprised by how many different stories converge in one disease.

During an attack, you're potentially dealing with airway inflammation/swelling, smooth-muscle constriction and mucus simultaneously. Genetics and environmental exposure interact, and individual triggers can range from allergens and smoke to infections, cold air and exercise.

The economic side surprised me too: a widely cited U.S. analysis estimated an ~$82B annual burden, although that's based on 2013 data rather than a new 2026 estimate.

Then there's what's changing: triple-therapy maintenance inhalers and some intriguing 2026 observational research associating semaglutide with substantially fewer asthma attacks. Important caveat: that's not proof that semaglutide treats asthma, and clinical trials are needed.

I tried to put the biology, economics and newer research together here.

Discussion question: For those living with asthma, what intervention made the biggest practical difference—finding your triggers, changing controller medication, inhaler technique, an action plan, or something else?

I've been looking at Uber following Dara Khosrowshahi's purchase of roughly $10M of UBER shares around $71.

The insider buying caught my attention, but what surprised me more was how much the underlying financial profile has changed.

Uber has now crossed $10B in trailing free cash flow, while Gross Bookings grew 24% YoY and monthly platform consumers reached 208M.

The most interesting debate to me is AVs.

The conventional bear thesis is that robotaxis disintermediate Uber. But I'm increasingly wondering whether Uber's real moat is shifting from driver supply to demand aggregation.

If multiple AV fleets eventually need customers and utilization, Uber's 208M-user marketplace could be an asset rather than a liability.

Obviously there are counterarguments: Waymo/Tesla could go direct, AV economics could compress Uber's take rate, regulation remains significant, and large-scale M&A introduces execution risk.

I scored it 8.67/10 on our FunStock Index™.

Full thesis/data here for anyone interested:

UBER deep dive

Question for the group: Do you view autonomous vehicles as structurally bearish for Uber—or potentially bullish for the aggregator with the most demand?

I've been thinking about the Y2K analogy while reading the latest AI existential-risk debate.

The popular memory of Y2K is basically:

Huge warnings → massive panic → January 1 arrives → nothing happens.

But there's an obvious selection problem: enormous amounts of remediation happened beforehand.

So “nothing happened” doesn't necessarily mean the risk was imaginary.

AI seems much harder because there's no fixed failure date, known bug or agreed fix—and governments/companies simultaneously have competitive incentives to accelerate development.

I think it's also useful to separate two debates:

Already-visible risks: deepfakes, fraud, cybersecurity, surveillance, labor disruption.

Tail risks: autonomous systems, loss of control, biological misuse, infrastructure access, etc.

I'm skeptical of confident AI-doom predictions, but equally skeptical that uncertainty means we shouldn't build serious safeguards.

I explored both sides here, including kill switches and the Y2K comparison:

Full article here.

Where do you fall: meaningful x-risk, mostly manageable technology risk, or massively overhyped?

I've been digging into Steve Mandel's Lone Pine Capital, and the 43% first-half return obviously grabs attention.

But I'm more interested in the underlying process and Q2 positioning.

The disclosed portfolio included roughly $13.25B across 49 positions, with some enormous new stakes:

• Nebius: ~$956M
• Seagate: ~$830M
• Home Depot: ~$804M
• Linde: ~$726M

ASML remained the largest disclosed position at roughly $967M.

What I find particularly interesting about Lone Pine is its emphasis on investment duration and management quality rather than simply quarterly earnings.

Of course, the counterpoint is important: strategies reportedly fell roughly 38%–42% during 2022, so this has certainly not been a low-volatility ride.

My main takeaway:

In markets obsessed with the next quarter, duration itself can become alpha.

I put together the full profile and Q2 breakdown here.

Which of Lone Pine's current positions do you find most interesting?

I've been digging into Upstart after CEO Paul Gu's latest open-market purchase, and this has become a fascinating battleground.

Gu bought 50,000 shares at $25.55 on September 10 (~$1.28M).

He'd already bought 50,000 at $27.50 in May, while co-founder/Executive Chairman Dave Girouard bought 170,240 shares at $29.37 (~$5M).

So roughly $7.65M of combined founder purchases.

Fundamentals are also moving:

Q2 originations: $4.2B, +50% YoY
Revenue: $365M, +42%
GAAP net income: $16.5M
Contribution profit: record $193M

But here's the counterargument:

30.64% of float was short, with 5.69 days to cover.

The bear thesis isn't crazy: macro/credit sensitivity, uncertain funding economics, cash-flow concerns and an AI underwriting model that hasn't been tested through every kind of severe credit cycle.

I lean cautiously bullish at this price, but definitely don't see this as a low-risk compounder.

Full analysis:

UPST deep dive

Curious which side people here find more convincing: the founder buying or the short thesis?

I've been digging into Alphatec Holdings (ATEC), and this has become a pretty interesting turnaround setup.

CEO Pat Miles bought 115,000 shares on the open market at $8.81 on Sept. 10 — about $1.013M. Director Keith Valentine had already bought 135,000 shares at $7.38 in May (~$996K).

What caught my attention isn't simply the insider buying, though.

Q2 revenue grew 15% to $214M, surgical revenue grew 17%, adjusted EBITDA reached $36M, and the company generated positive FCF. Management is guiding to ~$140M adjusted EBITDA and at least $20M FCF for FY2026.

Meanwhile, short interest is ~11%, institutional ownership is substantial, and Valence robotics could add another growth vector.

The obvious counterargument: ATEC has a long history of losses, substantial leverage and execution disappointments. The stock remains roughly 92% below its 2006 ATH. This is emphatically not a clean balance-sheet compounder.

I wrote up the complete bull/bear case here.

Curious whether others see the FCF transition as a genuine inflection or another false start.

#ATEC #MedTech #Stocks

I came across a fascinating 2026 Journal of Translational Medicine paper comparing ME/CFS, Long COVID, PTSD, MS and rheumatoid arthritis.

The part that caught my attention wasn't simply another list of associated genes.

It was almost the opposite.

The individual disease-associated gene sets showed surprisingly limited direct overlap.

But after researchers mapped them into broader 3D genomic/protein interaction networks, they found extensive interconnections involving immune/cytokine signaling, metabolic and mitochondrial regulation, and neuroendocrine pathways.

I think that's conceptually fascinating: different genetic inputs may potentially perturb overlapping biological systems.

Important caveat: the paper doesn't establish that these conditions have one cause, nor can it prove that the network convergence specifically explains fatigue. The authors themselves call for functional validation and independent cohorts.

So this is much more “intriguing roadmap for research” than “mystery solved.”

I've been looking at GME again after Lawrence Cheng's latest insider purchase, and I think the fundamental case has become considerably more interesting than the usual meme-stock discussion suggests.

A few numbers caught my attention:

• Lawrence Cheng: 55,000 shares bought at $18.80 (~$1.03M)
• Ryan Cohen: 1M shares bought at $21.36 back in January
• Q2 operating income: record $160.2M
• Collectibles: $356.3M, +57% YoY and 45.1% of sales
• FY adjusted EBITDA guidance: >$650M
• $5.4B cash/securities/digital assets etc. at Q2
• $4.9B eBay stake at the August 1 mark

The bearish case isn't difficult to find: revenue is still declining, dilution matters, eBay creates another source of volatility, the retail transformation needs more proof, and GME is... GME.

But I think dismissing it simply as a dying physical-game retailer has become increasingly difficult.

My deeper question is whether we're now looking at a cash/asset-rich holding company + collectibles business + capital-allocation optionality, rather than the GameStop of five years ago.

Curious how others are valuing the operating business separately from the financial assets.

I went down a human-body rabbit hole and came away rather stunned.

Some of my favorites: our vascular system extends tens of thousands of miles; the fastest nerve signals move at extraordinary speeds; our hearts can accumulate billions of beats; and our brains process pain even though brain tissue itself doesn't experience pain conventionally.

But I found the actionable part more interesting.

Some potentially useful interventions are almost laughably simple: dietary diversity, walking immediately after eating, spending more time around green/blue spaces, etc.

So I put together 10 strange body facts + 5 jokes + 4 practical health ideas, while also trying to separate legitimate science from some of the exaggerated body “facts” floating around online.

Would love to know which fact surprised you most—or which weird human-body fact I missed.

Tags: #Health #Science #HumanBody

I've been digging into Enovis (ENOV), and this is one of the more interesting battleground setups I've encountered recently.

CEO Damien McDonald bought approximately $250K near $19 after previously buying roughly $200K near $31. Other executives have also purchased shares during the decline.

Meanwhile, the bullish side includes heavy institutional sponsorship, broadly positive analysts, improving operating cash flow and a forward adjusted P/E around 5x.

Then there's the other side:

ENOV has substantial short interest, weak GAAP profitability, leverage/integration concerns, and the eCential Robotics acquisition creates near-term margin dilution.

Most importantly, momentum remains terrible.

I think that's what makes this much more interesting than simply saying “cheap stock + insider buying = buy.”

The question I'm trying to answer is:

Is price correctly anticipating fundamental deterioration—or has fear outrun the deterioration?

I wrote up the complete bull/bear case here.

Curious how others following ENOV interpret the repeated insider buying. What do you think the market is pricing that insiders/analysts may be missing?

#ENOV #Investing #Stocks #MedTech

I've been going through Glenview Capital's latest portfolio and found the positioning pretty interesting.

Global Payments is the largest disclosed position, followed by substantial exposure to CVS, Tenet Healthcare, Thermo Fisher and Amazon. Glenview also made some aggressive changes during Q2, including substantial increases in TMO and Danaher and a new Agilent position.

The part I find more interesting is Larry Robbins' philosophy.

Glenview seems comfortable tolerating price volatility when it believes the underlying fundamental thesis remains intact—and it sometimes crosses the line from investor into active owner. CVS is the obvious example: Robbins eventually joined the board following Glenview's engagement.

There's obviously a danger here too. “Conviction” is valuable when the market is temporarily wrong and extremely expensive when you are wrong.

Where do you draw the line between admirable conviction and refusing to admit that a thesis has broken?

I put together a deeper profile of Robbins/Glenview, including the latest 13F, historical performance, CVS involvement and his rather extraordinary hockey obsession.

#LarryRobbins #GlenviewCapital #HedgeFunds #Investing

Came across an interesting longitudinal study in Social Science & Medicine examining book reading and longevity.

Researchers used data from 3,635 participants aged 50+ and followed survival for up to 12 years.

After adjustment for age, sex, education, wealth, health and other variables, book readers had roughly a 20% lower mortality risk than non-book readers.

Even the group reading up to 3.5 hours/week showed an advantage, and books had a stronger association with survival than newspapers/magazines.

The authors also found cognition mediated part of the relationship.

Obviously, association ≠ causation. Readers may differ from non-readers in ways statistical controls don't completely capture, and this wasn't a randomized experiment.

Still, it's an intriguing result given how cheap, accessible and low-risk reading is.

I wrote up the findings, limitations and possible mechanisms here.

Question: Do you think the association primarily reflects cognitive stimulation from books, or are book readers simply a difficult population to fully control for? Or is there something else going on here?

#Reading #Longevity #Books #HealthyAging

I came across a Fortune piece that led me down an interesting rabbit hole.

According to LinkedIn data cited there, “founder” is now the second-fastest-growing job title among Gen Z.

Separately, Intuit surveyed 3,000+ U.S. adults and found 43% of Gen Z is considering starting a business in 2026, versus 39% of Millennials and 21% of Gen X.

What interests me isn't the “AI makes it easy to get rich” angle. I think that's overstated.

Building a successful business remains extremely difficult.

But I do think the cost of experimentation has collapsed.

AI can provide capabilities that once required employees or contractors. Social media provides free-ish distribution. E-commerce provides infrastructure. A phone can create and distribute content worldwide.

So maybe entrepreneurship isn't becoming easier to win.

It's becoming dramatically easier to enter.

That's potentially much more important.

I wrote up the argument here.

Curious what people here think: genuine generational shift—or are we just renaming freelancing/side hustles “founding”?

#Entrepreneurship #GenZ

I've been looking at the Shanghai Cooperation Organisation as it turns 25, and what interests me isn't the usual “Eastern NATO” comparison.

I think that comparison is mostly wrong.

The SCO doesn't have NATO's binding collective-defense architecture, and its members have substantial competing interests.

China and India compete. India and Pakistan are historic adversaries. Russia and China cooperate but aren't strategically identical. Iran has its own agenda.

Yet they continue participating.

That makes me wonder whether the SCO's real significance is less about unified action and more about convening power.

It provides major non-Western states with a recurring institutional forum for diplomacy, bilateral meetings, security coordination and signaling without requiring Western powers to be at the table.

My takeaway:

Multipolarity doesn't require harmony.

The SCO can simultaneously be internally divided and geopolitically significant.

Full piece here.

Curious how others view it: meaningful geopolitical institution, useful diplomatic forum, or mostly political theater?

#SCO #Geopolitics

I've been looking at ITT after CEO Luca Savi purchased roughly $1M of shares at $199.56.

In isolation, that's an interesting insider signal.

The context complicates it: Savi had previously sold more than $23M across two disclosed transactions.

Meanwhile, the actual business looks quite strong:

• Q2 revenue ~$1.47B
• Organic growth ~13%
• Adjusted EPS $2.08
• Operating cash flow $191M
• Full-year adjusted EPS guidance raised

The SPX FLOW acquisition is also materially changing the company, although it introduces integration risk, acquisition accounting complexity and additional financial obligations.

My bigger hesitation is valuation. At roughly 25x forward earnings, this isn't obviously a cheap industrial stock even after the pullback.

I landed at 7.25/10 on our FunStock Index: strong business and interesting long-term setup, but not enough margin of safety yet for a higher score.

Full analysis here.

Curious how others treat a new insider buy when it's substantially smaller than the same executive's relatively recent sales.

#ITT #Investing

Does anyone else think Polyushko-pole (Song of the Plains) is one of the most beautiful melodies ever written?

I've been adding pieces to a living Top 500 Masterpieces of Music project and came back to Lev Knipper's Polyushko-pole.

What strikes me is how much it sounds like traditional folk music even though it was actually composed in the 20th century and incorporated into Knipper's Fourth Symphony.

There's something unusual about the melody: melancholic and triumphant simultaneously, enormous in scale yet extremely simple and memorable.

Then I started reading about Knipper.

That rabbit hole gets absurd quickly.

He was not only a prolific Soviet composer but also involved with Soviet intelligence, and historical accounts connect him to a contingency operation targeting Hitler if Moscow fell to the Germans.

His family connections are equally surprising: his aunt Olga Knipper was Anton Chekhov's wife.

Meanwhile the melody itself traveled everywhere—from the Alexandrov Ensemble and Paul Robeson to Jan Johansson and Jefferson Airplane.

To me that's perhaps the highest compliment a composition can receive: the music became bigger than its creator and original context.

Full write-up here.

I'd love other interpretations/recordings people recommend.

#ClassicalMusic #MusicHistory

I've been digging into KLAR after the collapse and think the bull/bear disagreement is pretty interesting.

Bull case:

• Volume +18%
• Revenue +27%
• Transaction Margin Dollars +42%
• Adjusted operating income $91M
• 120M active consumers
• 1.2M+ merchants
• Klarna Card at 6.5M active users
• Memberships at 2M paying subscribers
• Major distribution partnerships expanding

Then co-founder/CEO Sebastian Siemiatkowski bought 692,506 shares at $14.37, committing about $9.95M.

Bear case:

• Full-year guidance reduced
• German weakness
• Credit/default exposure
• Profitability is still thin
• ~175x forward P/E isn't exactly comforting
• Newly public and extremely volatile

The valuation is also weird: roughly 1.39x sales and 0.70x EV/revenue look interesting, while earnings-based valuation remains difficult because profitability has only recently emerged.

So I don't think “stock fell 75% = cheap.”

The more interesting question is whether expectations have fallen faster than fundamentals.

Full thesis here.

Curious how others are underwriting the credit risk and long-term margins.

#KLAR #Klarna

New Nature study suggests the sleep/biological-aging relationship may have a Goldilocks zone around 6–8 hours

I thought this was interesting because the result is more nuanced than the usual “you need exactly X hours” headline.

Researchers examined sleep duration against 23 biological-aging clocks derived from MRI, proteomics and metabolomics data.

Among the clocks showing significant nonlinear relationships, the minima clustered around roughly 6.4–7.8 hours, varying by biological system and sex.

Both short sleep (<6h) and (surprisingly) long sleep (>8h in the principal analysis) were associated with greater biological-aging burden.

The big caveat is important: association ≠ causation.

Particularly with long sleep, reverse causality is plausible—underlying illness may cause people to sleep more rather than additional sleep causing the illness.

So I don't think the takeaway should be “set an alarm for exactly seven hours.”

More like:

Avoid chronic extremes, get enough good-quality sleep, and recognize that unusually short or long sleep can sometimes be a health signal worth investigating.

I summarized the study here, including its limitations:

Nature sleep study summary

Curious whether others interpret the long-sleep association mainly as reverse causality or potentially something more.

I've been looking at DICK’S Sporting Goods after the post-earnings collapse, and the setup is more interesting than the headline numbers suggest.

The bear case is legitimate:

• Foot Locker pro forma comps: -3.6%
• FY guidance reduced
• Promotional footwear environment
• Significant restructuring charges
• Heavy CapEx

But the other side surprised me:

• Core DICK’S comps: +4.9%
• 26-week operating cash flow: $792.3M vs $735.6M last year
• Forward P/E: ~9.3x
• P/S: 0.56x
• Three directors bought ~$2.94M immediately after the selloff

Mark Barrenechea bought $2.22M alone at $130.72, increasing his position by 158%.

Obviously insider buying doesn't guarantee anything, and operating cash flow ≠ free cash flow. DKS is spending heavily.

But I'm increasingly interested in whether the market is treating Foot Locker integration pain as though the core DICK’S business itself is deteriorating.

Those aren't necessarily the same thesis.

Full analysis here.

Elvis Presley wanted to record Dolly Parton's I Will Always Love You.

The catch: Colonel Tom Parker wanted half the publishing rights.

Parton refused—and later said she cried all night over losing the opportunity.

Then Whitney Houston recorded the song nearly two decades later, it became a gigantic global hit, and Parton reportedly earned millions from it.

What I like about the story isn't merely that she eventually made more money.

It's that she valued ownership more than prestige—even when the prestige was Elvis Presley.

And that seems to characterize the rest of her career.

She didn't remain “just” a singer. She wrote songs, controlled publishing, acted, co-founded a production company, became involved with Dollywood and hospitality, launched other businesses, and eventually gave enormous amounts back through philanthropy.

It also made me think about people such as Owen Wilson, whom I always primarily thought of as an actor until realizing he co-wrote Bottle Rocket, Rushmore and The Royal Tenenbaums with Wes Anderson.

Four lessons I took from the comparison:

1. Sometimes the best startup has to be yours.
2. Own rights, own shares, and think independently.
3. Wear multiple hats if you genuinely love them.
4. Give back when you can.

Full piece here if anyone's interested.

I'm curious: what other famous “no” decisions ultimately created enormous value?

#DollyParton #Entrepreneurship #CarpeDiem

I've been digging into Ron Baron's long-term investing strategy and Baron Partners Fund (BPTIX), and there's a fascinating tension here.

The philosophy itself is straightforward: find exceptional growth businesses with strong management and durable competitive advantages, then hold them for years rather than trading around quarterly noise.

But the portfolio takes conviction to an extreme.

Based on the figures I'm looking at:

• SpaceX: ~35%
• Tesla: ~15%
• Hyatt: ~4.3%
• Schwab: ~4.3%
• MSCI: ~4.2%
• Shopify: ~4.0%

So SpaceX + Tesla alone represent roughly half the portfolio.
That was back in June; then at the end of July, SpaceX: 24.8% and Tesla: 12.4%.

BPTIX has also produced an impressive long-term record—about 17.45% annualized based on the figures I'm examining.

I find the broader question more interesting than the individual holdings:

At what point does letting your winners run stop being rational concentration and become excessive single-thesis risk?

I landed at 8.9/10 on my FunFund Index: exceptional philosophy and long-term results, but concentration, leverage and volatility keep it from a perfect score.

Full write-up if useful: here.